Arena Pharmaceuticals — Investor Presentation (November 2020)
35 slides from Arena Pharmaceuticals's investor presentation, Nov 18, 2020
Slide 1: November 2020 Nasdaq: ARNA
November 2020 • Nasdaq: ARNA Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about the Arena investment thesis, catalysts, value, our investigative stage drug candidates, including with respect to their potential (including t
Slide 3: 2020-22 Data Catalysts Expected: Pipeline
2020-22 Data Catalysts Expected** Pipeline: 4 Clinical stage assets*** 8 Disease Areas 2 Ph 3 5 Ph 2 Multiple Ph 2 & Ph 3 Data Readouts Expected Across Potential Best-in-Class Pipeline 1 IND each year 7 data readouts: 2 Preclinical assets 3 Therapeutic areas *$800M upfront payment, up to $400M miles
Slide 4: Catalyst Horizon
Catalyst Horizon* H2 2020 H1 2021 H2 2021 H1 2022 H2 2022 Etrasimod AA Ph 2 Data Etrasimod ELEVATE UC 52 Ph 3 Data APD418 Ph 2a Data Etrasimod CULTIVATE (CD) Ph 2 Dose-Ranging Data Olorinab CAPTIVATE (IBS Pain) Ph 2b Data Etrasimod Complete ELEVATE UC 52 Enrollment Etrasimod ELEVATE UC 12 Ph 3 Data
Slide 5: Etrasimod
Etrasimod Investigational, Oral, Next Generation, S1P Receptor Modulator with Potential for Optimized Activity Being Evaluated for Multiple Immune-Mediated Inflammatory Diseases (IMID), Targeting ~$48B Market with Current Indications AD DRG Landscape Report 2018
Slide 6: Etrasimod in Gastrointestinal Conditions
Etrasimod in Gastrointestinal Conditions Ulcerative Colitis (UC), Crohn’s Disease (CD) & Eosinophilic Esophagitis (EoE)
Slide 7: Etrasimod: Potential Best-in-Disease S1P Receptor Modulator
Etrasimod Potential Best-in-Disease S1P Receptor Modulator with Broad Potential Applicability 60-80% $24B+ Market Opportunity Across GI3 of IBD patients currently not in remission at 1 Year1,2 Receptor Pharmacology Highly specific S1P1,4,5 No evidence of off-target activity Pharmacodynamics Rapid On
Slide 8: Etrasimod Ph2 Demonstrated Strong Efficacy Across Multiple Mayo Scores
Etrasimod Ph2 Demonstrated Strong Efficacy Across Multiple Mayo Scores and Rapid Improvement in Clinical Symptoms 4-Domain OASIS1 3-Domain OASIS1 Patients with TMCS ≤ 2 points and No Subscore > 1 point N=54 N=50 Clinical Remission defined as RB= 0; Endoscopic Improvement = 0,1; SF= 0,1 (per FDA draf
Slide 9: Phase 2 Safety Results
Phase 2 Safety Results Adverse events were predominantly mild to moderate No serious adverse events (SAEs) at the 2 mg dose Impact on HR and AV conduction was low throughout the study with no discontinuations related to bradycardia or AV block. No SAEs related to HR changes or AV block No cases of s
Slide 10: Etrasimod Global Phase 3 Program in UC
Etrasimod Global Phase 3 Program in UC Moderately to Severely Active UC 52-Week Treat-Through* Adults Biologics / JAK inhibitor Endpoints Primary Endpoint Trial 1: Week 12, week 52 clinical remission (modified MCS) Primary Endpoint Trial 2: Week 12 clinical remission (modified MCS) ~370 patients ~33
Slide 11: GLADIATOR-UC – Expected to Initiate Early 2021
GLADIATOR-UC – Expected to Initiate Early 2021 Subject Screening: During ELEVATE UC enrollment period After ELEVATE UC completes enrollment MMS 4-9, with ES ≥ 2 & RB ≥1 MMS 4-6, with ES ≥ 1 MMS 4-6, with ES ≥ 1 November 2020 • MMS: Modified Mayo Score; ES: Endoscopic Score; RB: Rectal Bleeding
Slide 12: Etrasimod Ph 2/3 Program in Crohn's Disease
Etrasimod Ph 2/3 Program in Crohn’s Disease The addition of Sub-Study A to the Ph 2/3 CULTIVATE program is expected to provide supportive data (safety, tolerability, efficacy) for dose selection and facilitate Ph 2 dose-ranging data in 2021 Primary Efficacy Endpoints ‡ Proportion of subjects with en
Slide 13: Etrasimod Aims to Address Unmet Need in Eosinophilic Esophagitis
Etrasimod Aims to Address Unmet Need in Eosinophilic Esophagitis (EoE) Strong Preference for Oral non-steroid Treatment Option Chronic allergen- driven IMID of the esophagus1,2 Expansion & infiltration of multiple immune cell subsets (dendritic, CD4+, CD8+, eosinophil, mast) Th2 cytokine profile (IL
Slide 14: Etrasimod in Dermatologic Conditions
Etrasimod in Dermatologic Conditions Atopic Dermatitis (AD) Alopecia Areata (AA)
Slide 15: Etrasimod Aims to Address Unmet Need in Atopic Dermatitis
Etrasimod Aims to Address Unmet Need in Atopic Dermatitis 1. Bieber T. NEJM 2008, 358;14: 1483-1494; 2: Guttman-Yassky et al. JACI 2011; 127(6):1420-1431; 3. Renert-Yuval Y and Guttman-Yassky E. AAAI 2020, 124:28-35 1. 4. Silverberg, JI. Dermatol Clin. 2017 Jul;35(3):283-289.; 5. Barbarot S, et al.
Slide 16: Etrasimod Phase 2b Trial for AD
Etrasimod Phase 2b Trial for AD A Phase 2b Placebo-Controlled, Dose Finding Trial to Assess the Safety and Efficacy of Etrasimod in Patients with Moderate-to-Severe AD Primary Endpoint Percent change in Eczema Area and Severity Index (EASI) from baseline to week 12 Secondary Endpoint Proportion of p
Slide 17: Etrasimod in AD
Etrasimod in AD Showed statistically significant improvement at week 12 on the vIGA responder criteria, which is the FDA Ph 3 primary endpoint Demonstrated early and statistically significant effect at week 4 across EASI, EASI-75, and pruritus endpoints No plateau effect at week 12 The overall safet
Slide 18: Proportion of Participants Achieving vIGA Success or EASI-75
Proportion of Participants Achieving vIGA Success or EASI-75 CMH, Cochran-Mantel-Haenszel; FAS, Full Analysis Set; NRI, non-responder imputation vIGA of 0 or 1 and a Reduction from Baseline of ≥ 2 points EASI-75 * 2 mg p<0.05 (Wk 12) November 2020 • * 2 mg p<0.05 (Wk 4)
Slide 19: Etrasimod in AD – Efficacy in Range of Market Leaders
10% 30% 40% 50% 20% 60% 70% 0% Etrasimod in AD– Efficacy in Range of Market Leaders vIGA Success EASI-75 November 2020 • *Etrasimod Completer Analysis of Full Therapeutic Exposure at Week 12 for vIGA and EASI-75 Wk 12 Wk 16 Wk 12 Wk 16 Note: No direct head-to-head data available Caution advised when
Slide 20: Dermatologists Rate Safe & Effective Systemic as Greatest AD Need
AD DRG ATOPIC DERMATITIS/ATOPIC ECZEMA DISEASE LANDSCAPE & FORECAST 2020, pg 98 Dermatologists Rate “Safe & Effective Systemic” as Greatest Atopic Dermatitis Need Post Topical Therapy Failure Unmet Need Level of Attainment Importance g Current attainment g Future attainment Low Medium High Safe, eff
Slide 21: Safety and Simplicity Influence Treatment Decisions (Psoriasis)
0%50%100% Safety and Simplicity Heavily Influence Dermatologists’ Treatment Decisions (Psoriasis) AD DRG Landscape Report 2018 43 63 65 79 82 Enbrel Stelara Humira Cosentyx Skyrizi Drug Safety/Side Effects Route of Administration Efficacy (PASI-75) Market Leader Otezla GI side effects Oral 28% Humir
Slide 22: Safety and Simplicity Influence Treatment Decisions (Atopic Dermatitis)
Safety and Simplicity Heavily Influence Dermatologists’ Treatment Decisions (Atopic Dermatitis) AD DRG Landscape Report 2018 Drug Safety/Side Effects Route of Administration AD (IGA Response) Etrasimod* Per profile Oral 24% Dupixent ISR, Conjunctivitis Biologic Injectable 28% Upadacitinib Boxed Warn
Slide 23: Moving to Phase 3 in AD
Moving to Phase 3 in AD The efficacy and safety profile support moving expeditiously into a Ph 3 program* Phase 3 trials will require stringent management similar to ELEVATE UC Manage moderate to severe participant mix Safety and efficacy from Ph 2 expected to allow access to global, experienced cli
Slide 24: Etrasimod Aims to Address Unmet Need in Alopecia Areata
Etrasimod Aims to Address Unmet Need in Alopecia Areata Sources: 1. Gilhar et al. NEJM 2012; 366:1515-25 2. Harvard Medical School. Alopecia Areata. Published: 01/2019; 3. Lee S., Lee H, et al. Comorbidities in alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80:466-7
Slide 25: Olorinab
Olorinab Investigational Peripherally Acting, Highly–Selective, Full-Agonist to Cannabinoid Receptor 2 (CB2) for Gastrointestinal Pain
Slide 26: Olorinab Aims to Address an Unmet Need for Abdominal Pain
Olorinab Aims to Address an Unmet Need for Abdominal Pain Sources: 1. DRG: IBS Report (2015); 2. Drossman DA, et al. J Clin Gastroenterol. 2009 Jul; 43(6): 541–550.; 3. AGA Patient Survey, IBS In America, December 2015. 78% of IBS patients report recurring / continuous abdominal pain2 Olorinab Ratio
Slide 27: Shared Mechanisms in IBS and IBD Pain
Shared Mechanisms in IBS and IBD Pain Sources: 1. Barbara et al., (2014) Curr Opin Gastroenterol 30:352-358; 2. Cremon et al., (2017) Alimentary Pharmacology and Therapeutics 45:909-922; 3. Dr. Lin Chang, unpublished data; 4. Spiller and Major (2016), Nat Rev Gastroenterol Hepatol 13(10):613-21; 5.
Slide 28: Strong Signal in Average Abdominal Pain Score in Ph 2a
Strong Signal in Average Abdominal Pain Score (AAPS) and Responder Analysis in Ph 2a Δ AAPS from Baseline Average Peak Pain Responders AAPS Improvement -4.6 85% of patients improved at week 4 100% of patients improved at week 8 *=p<0.05; **=p<0.01 (Evaluable Population with ≥30% change from baseline
Slide 29: Olorinab Ph 2 Trial Evaluating Abdominal Pain in IBS
A Phase 2, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Patients with Irritable Bowel Syndrome (IBS) Experiencing Abdominal Pain Primary Endpoint Improvement in the weekly Average Abdominal Pain Scale (AAPS) from baseline to week 12 Study
Slide 30: APD418
APD418 Potential First-in-Class Investigational Beta-3 AdrR Antagonist and Cardiac Myotrope for Acute Heart Failure (AHF)
Slide 31: Significant Unmet Need in AHF
Significant Unmet Need in AHF Sources: 1. Heart Failure. Disease Landscape & Forecast. DRG. June 2018.; 2. Dharmarajan K, et al. BMJ. 2015 Feb 5;350:h411.; 3. Nielsen DV, et al. Anesthesiology. 2014 May;120(5):1098-108. Long-Awaited Innovative Approach to AHF 9.5M AHF hospitalizations in 20251 No ap
Slide 32: APD418 First-in-Class for AHF with Novel MOA
APD418 First-in-Class for AHF with Novel MOA – Improved Cardiac Function Without Hemodynamic Liability Image adapted from: Kulandavelu S and Hare JM. J Am Coll Cardiol. 2012;59(22):1988-1990; Moniotte S, et al. Circulation. 2001 Mar 27;103(12):1649-55. * P<0.05 vs Vehicle for EF; # P<0.05 vs Vehicle
Slide 33: Arena Pharmaceuticals
/AARI-NA PHARMACEUTICALS Nasdaq: ARNA
Slide 34: Additional Slide November 2020
Additional Slide November 2020
Slide 35: EASI-75 in Ongoing Open-Label Extension – Interim Data
EASI-75 in Ongoing Open-Label Extension (OLE) – Interim Data as of November 12, 2020 Data taken from live PowerBi snapshot (n=46 at Week 32) on 11/12/2020; these are interim data and may not reflect results of OLE. Graph shows the proportion of subjects achieving EASI-75 in the OLE relative to basel
Arena Pharmaceuticals — Investor Presentation (November 2020) on 6ix